Case Report: Scarring Alopecia Induced by Gefitinib

Gefitinib, an epidermal growth factor receptor inhibitor (EGFRI) used in cancer treatment, was associated with a rare case of cicatricial alopecia in a 59-year-old woman. After 7 months of gefitinib treatment, she experienced itching and hair loss on her scalp, characterized by erythematous hairless patches and thick crusts. Histopathological analysis revealed a decreased number of hair follicles, perifollicular lymphocyte infiltration, and perifollicular fibrosis, indicating scarring alopecia. This case highlighted a rare cutaneous side effect of gefitinib, expanding the understanding of its dermatological impacts.